Mylan (MYL) Says FY12 Cash Flow Could Be Used for Buybacks, M&A; Thinks PDUFA Regulation is 'Beneficial'

Article Stock Quotes (1) Comments (0)

Shares of Mylan, Inc. (NASDAQ: MYL) are continuing lower Monday as it makes a presentation at a Morgan Stanley healthcare conference today.

The pharma reaffirmed FY12 EPS expectations. Free cash flow is expected to reach $600 million in FY12, allowing for more M&A as well as buybacks, according to the company.

Additionally, Mylan says FDA regulation FDUFA is beneficial and that it is focused on expanding its generic portfolio.

Shares are about flat on the session after moving higher early.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Mylan (MYL) Launches Generic Tricor Tabs (ABBV)
• UPDATE: Student Loan Rates Set for Change; ITT (ESI) & Corinthian (COCO) on Move
• SciClone (SCLN) Notes Possible Q1 Revenue Impact Due to NovaMed Accounting

Create E-mail Alert Related Categories

FDA, Guidance, Trader Talk

Related Entities

Morgan Stanley

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?